Dakota Dunes
Dakota Dunes
Dakota Dunes, South Dakota, United States11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, complement 3 glomerulopathy, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 2 | 2026-09-03 | NCT06989359 | |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Chronic Disease, Chronic Kidney Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, kidney disorder, kidney failure, metabolic disease, type 2 diabetes mellitus, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT05099770 | |
| PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Phase 4 | 2026-08-03 | NCT07611214 | |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, diabetes mellitus, diabetic kidney disease, endocrine system disorder, glomerulonephritis, immune system disorder, kidney disorder, minimal change disease, nephritis, nephrosis, primary focal segmental glomerulosclerosis, urinary system disorder | Recruiting | Phase 2 | 2026-08-03 | NCT06466135 | |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-07-14 | NCT05248646 | |
| Study of BHV-1400 in IgA Nephropathy | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, proteinuria, urinary system disorder | Recruiting | Phase 1 | 2026-06-23 | NCT07054684 | |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Enrolling by invitation | Phase 2 / Phase 3 | 2026-05-05 | NCT05248659 | |
| CYPRESS Efficacy and Safety Study Extension | eye disorder, myopia, refractive error | Active, not recruiting | Not applicable | 2026-05-05 | NCT04947735 | |
| Control of Myopia Using Novel Spectacle Lens Designs | eye disorder, myopia, refractive error | Active, not recruiting | Not applicable | 2026-05-05 | NCT03623074 | |
| Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 2 | 2025-04-06 | NCT06740526 |